MA-NEC-ENERGY-SOLUTIONS
14.1.2020 14:02:10 CET | Business Wire | Press release
NEC Energy Solutions, Inc. (NEC ES), announced today it will provide 100MW of energy storage in Northern Ireland for the Gore Street Energy Storage Fund (GSF) and project developer Low Carbon. The 100MW of energy storage will comprise two 50MW projects located in Drumkee, County Tyrone and Mullavilly, County Armagh. The two projects, which are currently under construction, are the largest projects to date in Northern Ireland and are expected to derive revenue from the new Irish “Delivering a Secure Sustainable Electricity System” (DS3) program.
The System Operator of Northern Ireland has indicated that running the power system with increasingly high levels of renewable energy is a major challenge due to the intermittent nature of wind power and its technical characteristics. The purpose of the DS3 program is to enable Ireland to meet its target of 75% non-synchronous and renewable (i.e. wind and solar) electricity across the all-island network. The DS3 market consists of both fixed and standard contracts available across the Irish grid in both the Republic of Ireland and Northern Ireland.
“Northern Ireland has made tremendous progress adopting renewable energy. Last year 44% of electricity consumption was generated by renewable resources. This easily beats Northern Ireland’s renewable target of 40% and occurred one year ahead of its 2020 deadline. Energy storage, via the DS3 program makes more of this possible”, said Steve Fludder, CEO of NEC Energy Solutions. “We are pleased to extend our partnership with Gore Street Capital. We invested in the Gore Street Energy Storage Fund and we look forward to working with Gore Street Capital on these and future projects. We also have excellent experience with Low Carbon operating and maintaining their two projects in the UK and we’re eager to collaborate with them in Northern Ireland.”
NEC is providing turnkey engineering, procurement and construction (EPC) including its GSS® end-to-end grid storage solution and its AEROS® controls system, NEC’s proprietary energy storage control software. Both 50MW projects will be completed and commissioned in Q1 2021. This transaction marks the second tranche of projects that NEC has been awarded by both Gore Street and Low Carbon.
“We are pleased to award this important EPC contract to NEC Energy Solutions, one of Gore Street’s long-term strategic partners, following a significant competitive tender process. We chose NEC Energy Solutions because they have offered the optimal commercial and technical proposal,” commented Alex O’Cinneide, CEO of Gore Street Capital, the investment manager of Gore Street Energy Storage Fund PLC. “We look forward to working once again with NEC Energy Solutions on these significant projects, among the largest of their kind in Ireland. As investment in sources of volatile renewable generation to supply the grid in Ireland continues to increase, supported in particular by excellent wind generation potential, assets such as these will form a major step in advancing Ireland’s climate change objectives.”
About NEC Energy Solutions
NEC Energy Solutions designs, manufactures, and integrates smart energy storage solutions for the electric grid and applications with critical power needs. Its megawatt-scale energy storage and control systems provide greater stability to the grid while maximizing renewable generation, while in telecom, datacenter, and other industrial applications, its high performance lithium-ion battery systems provide better value than traditional lead-acid batteries in tough, critical power applications. Learn more at www.neces.com .
About Gore Street Energy Storage Fund Plc.
Gore Street Energy Storage Fund is the first publicly traded fund established to provide investors with a sustainable and attractive dividend over the long term by investing in a diversified portfolio of utility scale energy storage projects primarily located in the UK, North America and Western Europe. The fund went public on May 25, 2018 on the London Stock Exchange.
About Gore Street Capital
GSC is a private equity firm with a leading renewable investment expertise. Established in 2013, GS has provided a platform to acquire, develop and manage global renewable energy and has a highly experience management team. Gore Street has some energy storage experience – they have been behind the Cleveland Potash project in North Yorkshire, the Lower Road project in Brentwood, Essex and the Port of Tilbury project co-located with London’s Port of Tilbury. All projects included NEC Energy Solutions hardware and software.
NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners.
©2020 NEC Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005403/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom